文献速递细菌感染、耐药与抗菌药物

接受依库珠单抗治疗患者的播散性淋球菌感染:病例系列

Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该病例系列从FDA安全数据库和文献中检索2004年至2017年接受依库珠单抗后发生淋球菌感染的患者,共9例,其中8例(89%)为播散性感染,多数需住院、血培养阳性,部分需升压药或机械通气。提示依库珠单抗使用者可能比一般人群有更高的播散性淋球菌感染风险。

要点

  • 依库珠单抗抑制终末补体激活,可能增加播散性淋球菌感染风险。
  • 9例淋球菌感染中8例为播散性,7例血培养阳性,8例需住院。
  • 处方者应教育患者风险并按CDC指南筛查性传播疾病。

核心结论

  • 接受依库珠单抗的患者可能比一般人群有更高的播散性淋球菌感染风险。

研究设计与样本

  • 纳入标准为淋球菌感染前3个月内至少接受1剂依库珠单抗。

主要发现

  • 共识别9例淋球菌感染,其中8例(89%)分类为播散性感染。
  • 播散性感染病例中,8例需住院,7例血培养阳性,2例需血管升压药支持。
  • 1例需机械通气;1例淋球菌感染可能对死亡前并发症有贡献,但报告者将死亡归因于基础疾病。

临床怎么用

  • 处方者应教育接受依库珠单抗的患者其严重淋球菌感染风险。
  • 按CDC性传播疾病治疗指南进行筛查,或在疑似病例中筛查。
  • 若在依库珠单抗治疗期间使用抗菌药物预防,应考虑淋球菌抗菌药物敏感性趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gonorrhea is the second most commonly reported notifiable condition in the United States. Infrequently, Neisseria gonorrhoeae can cause disseminated gonococcal infection (DGI). Eculizumab, a monoclonal antibody, inhibits terminal complement activation, which impairs the ability of the immune system to respond effectively to Neisseria infections. This series describes cases of N. gonorrhoeae infection among patients receiving eculizumab. METHODS: Pre- and postmarketing safety reports of N. gonorrhoeae infection in patients receiving eculizumab worldwide were obtained from US Food and Drug Administration safety databases and the medical literature, including reports from the start of pivotal clinical trials in 2004 through 31 December 2017. Included patients had at least 1 eculizumab dose within the 3 months prior to N. gonorrhoeae infection. RESULTS: Nine cases of N. gonorrhoeae infection were identified; 8 were classified as disseminated (89%). Of the disseminated cases, 8 patients required hospitalization, 7 had positive blood cultures, and 2 required vasopressor support. One patient required mechanical ventilation. Neisseria gonorrhoeae may have contributed to complications prior to death in 1 patient; however, the fatality was attributed to underlying disease per the reporter. CONCLUSIONS: Patients receiving eculizumab may be at higher risk for DGI than the general population. Prescribers are encouraged to educate patients receiving eculizumab on their risk for serious gonococcal infections and perform screening for sexually transmitted diseases (STDs) per the Centers for Disease Control and Prevention STD treatment guidelines or in suspected cases. If antimicrobial prophylaxis is used during eculizumab therapy, prescribers should consider trends in gonococcal antimicrobial susceptibility due to emerging resistance concerns.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Crew PE, Abara WE, McCulley L, et al. Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series. Clin Infect Dis. 2019. PMID: 30418536. doi:10.1093/cid/ciy958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。